Enlightening article review by Buell:

‘Hybrid potatoes: Rooting for heterosis’

tinyurl.com/jesfhwk2

#WIS

#PlantandEnvironmentalScience

#Homozygous

#Heterozygous

#Potato

#Rice

#Maize

#Solanaceae

#IncreasedVigour

#AgriculturalProductivity

#Genome

#Progeny

#GeneticLoad

C. Robin Buell:

Enlightening article review by Buell:

‘Hybrid potatoes: Rooting for heterosis’

tinyurl.com/jesfhwk2

#WIS

#PlantandEnvironmentalScience

#Homozygous

#Heterozygous

#Potato

#Rice

#Maize

#Solanaceae

#IncreasedVigour

#AgriculturalProductivity

#Genome

#Progeny

#GeneticLoad

Fig.1

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? www.thelancet.com/journals/lan...
#zodasiran #HoFH #LDL #cholesterol

#MedSky #EndoSky #CardioSky

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial Quarterly dosed zodasiran shows evidence of reductions in LDL cholesterol with a favourable safety profile, in patients with HoFH receiving background lipid-lowering therapy. Further investigation in ...

Quarterly dosed #zodasiran shows evidence of reductions in #LDL #cholesterol with a favourable safety profile, in patients with #HoFH receiving background lipid-lowering therapy www.thelancet.com/journals/lan...
#homozygous #familial #hypercholesterolaemia

#MedSky #EndoSky #CardioSky

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

New—Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with #homozygous #familial #hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial The LDL cholesterol response was highly variable, but generally similar in patients treated with both lerodalcibep and evolocumab. Importantly, the study showed the inability to predict response based...

Lerodalcibep and evolocumab for the treatment of #homozygous #familial #hypercholesterolaemia with #PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial www.thelancet.com/journals/lan...
#HoFH #LDL #cholesterol